- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02072070
Efficacy and Safety Study of TissueGene-C to Degenerative Arthritis
A Placebo Controlled, Double-blind, Randomized, Parallel-group, Multi-center Phase III Study to Determine the Efficacy and Safety of TissueGene-C in Patients With Degenerative Arthritis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
TissueGene-C is a biological new drug which consists of normal chondrocyte cells and transduced chondrocyte cells that express growth factor to modify osteoarthritis symptom for long term period.
During the Phase 3 clinical trial , we will compare TissueGene-C to placebo in 26, 52 weeks trial with 156 outpatients who have osteoarthritis. The outpatients are randomized to TissueGene-C or placebo in 1:1 ratio, and they will be monitored and recorded in terms of alleviating symptoms, sports activities, function of the knee, and the presence of adverse events.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Cheongju, Korea, Republic of, 361-711
- Chungbuk National University Hospital
-
Daegu, Korea, Republic of, 700-721
- Kyungpook National Univ. Hospital
-
Incheon, Korea, Republic of, 400-711
- Inha University Hospital
-
Jeonju, Korea, Republic of, 561-712
- Chonbuk National University Hospital
-
Seoul, Korea, Republic of, 135-710
- Samsung Medical Center
-
Seoul, Korea, Republic of, 138-736
- Asan Medical Center
-
Seoul, Korea, Republic of, 110-744
- Seoul National University Hospital
-
Seoul, Korea, Republic of, 137-701
- The Catholic University of Korea Seoul St. Mary's Hospital
-
Seoul, Korea, Republic of, 100-032
- Inje University Seoul Paik Hospital
-
Seoul, Korea, Republic of, 158-710
- Ewha Womans University Mokdong Hospital
-
Seoul, Korea, Republic of, 133-791
- Hanyang University Medical Center
-
Ulsan, Korea, Republic of, 682-714
- Ulsan University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female patients at least 19 years of age
- Patients diagnosed with degenerative arthritis
- Patients with IKDC(Knee Documentation Committee subjective score) score of 60 or below
- Patients with 100 mm VAS(Visual Analog Scale) score of 40 or above
- With Grade 3 osteoarthritis as determined by the radiographic criteria of Kellgren and Lawrence
- With an International Cartilage Repair Society(ICRS) Grade III or IV cartilage damage in the major lesions, as confirmed through an MRI scan
- With a Body Mass Index(BMI) of higher than18.5 and lower than 30
Patients who satisfies the clinical/radiational criteria by the American College of Rheumatology (ACR) guidelines, and applies to one of the following.
- Older than 50
- Morning stiffness for less than 30 minutes
- Crepitus and Osteophytes
- With major lesions concentrated in one section of the knee, and with the major lesions considered the main cause of the clinical symptoms
- With no alleviation of the symptoms even after at least three months of non-surgical treatment
- Healthy, with no major findings from the physical examination, hematology, serum chemistry, and urine tests, and no significant medical history
- Agreed to use an effective contraceptive method during the study period
- Voluntarily agreed to participate in this study, and signed the informed consent form
Exclusion Criteria:
- Showed clinically significant hematology, serum chemistry, and urine test results at the screening visit
Regarding inclusion criteria 6. following patients should not be included
- patients with a major lesion of ICRS grade 4 which is larger than 6cm2(for patient with ICRS grade 4)
- patients with a major lesion of ICRS grade 3 which is larger than 6cm2(for patient without a ICRS grade 4),
- Patient who had skin disease around target knee
- patients who have a positive skin reaction to CS-10
- Patients who had been administered with drugs such as oriental medicine, glucosamine and chondroitin within 14 days of baseline visit
- Patients taking steroidal anti-inflammatory medications within 14 days of baseline visit
- Patients with severe pain in other areas that could effect the diagnosis of the symptoms of the
- History of surgery like arthroendoscopy within the past 6 months on the target knee
- Patients who had been administered with immunosuppressants, including antirheumatic drugs (including methotrexate or antimetabolite), within the past 3 months
- Patients who had been treated with physical therapy or herbal remedy (acupuncture, heat etc.) within 2 weeks of baseline visit
- History of injection within the past 3 months on the target knee
- Pregnant or breastfeeding female
- With another joint disease apart from degenerative arthritis (e.g., systemic rheumatic inflammatory disease associated with the knee or chondrocalcinosis, hemachromatosis, inflammatory arthritis, necrosis of the trochanter, Paget's disease adjacent to a joint in the femur or tibia, ochronosis, hemophilic arthropathy, infectious arthritis, Charcot's disease in the knee joint, villonodular synovitis, synovial chondromas)
- With an infectious disease, including HIV or hepatitis
With any of the following clinically significant diseases:
- heart disease (e.g., myocardial infarction, arrhythmia, other serious heart diseases, coronary artery bypass graft)
- kidney disease (e.g., chronic renal failure, glomerulonephritis)
- liver disease (e.g., liver cirrhosis, fatty liver, acute or chronic liver disease)
- endocrine disease (e.g., hyperthyroidism, hypothyroidism, thyroiditis, diabetes insipidus, Cushing's disease)
- insulin-dependent diabetes mellitus
- medical history of past or current malignant tumor
In particular, the tumors that TissueGene-C may aggravate can be screened using the following tests:
- Leukemia (White Blood Cell level in the hematology)
- Osteochondroma, Chondromas, Chondroblastoma, Chondromyxoid fibroma, Chondrosarcoma (Alkaline phosphatase level in the hematology)
- Participated in another clinical trial (using the investigational drug or a medical device) within 30 days before enrollment in this study
- Patients who administered the TissueGene-C from past clinical trial
- Considered inappropriate by the investigator for participation in this study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: TissueGene-C
Single intra-articular injection to the damaged knee joint at a dose of 1.8 x 10^7 cells
|
TissueGene-C at 1.8 x 10^7 cells
|
PLACEBO_COMPARATOR: Placebo
Single intra-articular injection to the damaged knee joint
|
Placebo control(Normal Saline)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in IKDC scores
Time Frame: Week 0 and 52
|
Symptoms, sports activities, and function of the knee will be measured by the International Knee Documentation Committee (IKDC)
|
Week 0 and 52
|
Changes in 100 mm VAS scores
Time Frame: Week 0 and 52
|
Pain of the knee will be measured by the 100mm Visual Analogue Scale (VAS)
|
Week 0 and 52
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in WOMAC scores
Time Frame: Wekk 0, 26, 39 and 52
|
Pain, stiffness, and physical function of the knee will be measured by the Western Ontario and McMaster Universities (WOMAC)
|
Wekk 0, 26, 39 and 52
|
Changes in KOOS scores
Time Frame: Week 0, 26, 39 and 52
|
Symptoms, pain and functionality of the knee joint will be evaluated via the Knee Injury and Osteoarthritis Outcome Score (KOOS)
|
Week 0, 26, 39 and 52
|
Changes in MRI scan
Time Frame: Week 0, 26 and 52
|
Comparison of pre-procedure MRI scans to those obtained at pre-dosing and at months 6 and 12 following dosing by an independent radiographic reviewer.
|
Week 0, 26 and 52
|
Changes in Joint Space Width by an independent radiographic reviewer.
Time Frame: Week 0, 26 and 52
|
Week 0, 26 and 52
|
|
Level of Biomarkers in blood and urine.
Time Frame: Week 0, 26, 39 and 52
|
Week 0, 26, 39 and 52
|
|
Proportion of Patients Use of Rescue Medication.
Time Frame: Week 4, 12, 26, 39 and 52
|
Week 4, 12, 26, 39 and 52
|
|
Changes in IKDC scores
Time Frame: Week 0, 26 and 39
|
Symptoms, sports activities, and function of the knee will be measured by the International Knee Documentation Committee (IKDC)
|
Week 0, 26 and 39
|
Changes in 100 mm VAS scores
Time Frame: Week 0, 26 and 39
|
Pain of the knee will be measured by the 100mm Visual Analogue Scale (VAS)
|
Week 0, 26 and 39
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Seong Il Bin, MD, PhD, Asan Medical Center
- Principal Investigator: Myung Gu Kim, MD, PhD, Inha University Hospital
- Principal Investigator: Jin Gu Kim, MD, PhD, Inje University
- Principal Investigator: Su Hee Kyung, MD, PhD, Kyungpook National University Hospital
- Study Chair: Myung Chul Lee, MD, PhD, Seoul National University Hospital
- Principal Investigator: Yong In, MD, PhD, The Catholic University of Korea Seoul ST. Mary's Hospita
- Principal Investigator: Seong Do Cho, MD, PhD, Ulsan University Hospital
- Principal Investigator: Jae Doo Yoo, MD, PhD, Ewha Womans University Mokdong
- Principal Investigator: Ju Hong Lee, MD, PhD, Chonbuk National University Hospital
- Principal Investigator: Ui Seong Choi, MD, PhD, Chungbuk National University Hospital
- Principal Investigator: Chung Hyeok Choi, MD, PhD, Hanyang University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- KS-TGC-01-3
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Degenerative Arthritis
-
Smith & Nephew, Inc.TerminatedDegenerative Arthritis of KneeUnited States, Australia
-
Schulthess KlinikWinterthur Institute of Health Economics (WIG), SwitzerlandCompletedRotator Cuff Tear | Rotator Cuff Tear Arthropathy | Trapeziometacarpal Osteoarthritis | Degenerative Arthritis of Left Glenohumeral Joint | Degenerative Arthritis of Right Glenohumeral JointSwitzerland
-
Seoul National University Bundang HospitalCompletedAvascular Necrosis of Femoral Head | Degenerative Arthritis of HipKorea, Republic of
-
DePuy OrthopaedicsTerminatedOsteoarthritis | Post-traumatic Arthritis | Non-inflammatory Degenerative Joint DiseaseUnited States
-
Stryker Australia Pty Ltd.Not yet recruitingArthritis (E.G., Degenerative Joint Disease (DJD), Osteoarthritis, and Rheumatoid Arthritis (RA))Australia
-
R-BioNot yet recruitingKnee Arthritis | Degenerative Arthritis
-
R-BioNot yet recruitingKnee Arthritis | Degenerative ArthritisKorea, Republic of
-
Smith & Nephew, Inc.TerminatedOsteoarthritis | Degenerative Arthritis | Traumatic ArthritisUnited States
-
Wrightington, Wigan and Leigh NHS Foundation TrustCompletedInflammatory Arthritis | Degenerative ArthritisUnited Kingdom
Clinical Trials on TissueGene-C
-
Kolon Life ScienceCompletedDegenerative ArthritisKorea, Republic of
-
Kolon Life ScienceCompletedDegenerative ArthritisKorea, Republic of
-
Kolon TissueGene, Inc.CompletedOsteoarthritis, KneeUnited States
-
Kolon Life ScienceCompletedDegenerative ArthritisKorea, Republic of
-
Kolon Life ScienceCompletedDegenerative ArthritisKorea, Republic of
-
Kolon TissueGene, Inc.Not yet recruitingDegenerative Osteoarthritis
-
Kolon TissueGene, Inc.Active, not recruitingDegenerative OsteoarthritisUnited States
-
Kolon TissueGene, Inc.RecruitingDegenerative OsteoarthritisUnited States
-
Kolon TissueGene, Inc.CompletedOsteoarthritis, KneeUnited States
-
IlDong Pharmaceutical Co LtdCompleted